Novartis AG
Develops and markets innovative medicines globally using advanced science and technology.
NOVN | SW
Overview
Corporate Details
- ISIN(s):
- CH0012005267 (+10 more)
- LEI:
- 5493007HIVTX6SY6XD66
- Country:
- Switzerland
- Address:
- LICHTSTR. 35, 4056 BASEL
- Website:
- https://www.novartis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Novartis AG is a global innovative medicines company dedicated to the research, development, manufacturing, and marketing of a broad range of healthcare products. The company's core mission is to reimagine medicine to improve and extend people's lives. By utilizing advanced science and digital technologies, Novartis focuses on creating transformative treatments in areas of significant medical need. Its portfolio serves patients, healthcare professionals, and societies worldwide through the development of pharmaceuticals and other therapeutic solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-07 08:30 |
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža družbe Sandoz AG
|
Slovene | 2.2 MB | ||
| 2023-08-07 08:30 |
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža družbe Novartis Pharma AG
|
Slovene | 4.4 MB | ||
| 2023-08-07 08:30 |
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža
|
Slovene | 2.4 KB | ||
| 2019-10-22 08:00 |
Earnings Release
Novartis delivered another strong quarter with double digit sales growth and co…
|
English | 138.9 KB | ||
| 2019-10-08 08:15 |
Regulatory News Service
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gai…
|
English | 28.9 KB | ||
| 2019-10-02 08:15 |
Regulatory News Service
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing…
|
English | 21.0 KB | ||
| 2019-09-29 17:30 |
Earnings Release
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3…
|
English | 25.3 KB | ||
| 2019-09-17 08:15 |
Legal Proceedings Report
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indic…
|
English | 24.4 KB | ||
| 2019-08-30 08:15 |
Regulatory News Service
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-hea…
|
English | 24.4 KB | ||
| 2019-07-29 08:00 |
Regulatory News Service
Novartis provides update on Phase III PARAGON-HF trial in heart failure patient…
|
English | 29.7 KB | ||
| 2019-07-18 08:00 |
Earnings Release
Novartis delivers strong sales, double digit core operating income growth and l…
|
English | 137.7 KB | ||
| 2019-07-01 18:30 |
M&A Activity
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic p…
|
English | 19.0 KB | ||
| 2019-06-07 08:00 |
Board/Management Information
Novartis announces new leader of Pharmaceuticals Business Unit
|
English | 18.1 KB | ||
| 2019-04-24 08:00 |
Earnings Release
Novartis starts 2019 with strong sales and double digit core1 operating income …
|
English | 95.6 KB | ||
| 2019-03-27 00:35 |
Regulatory News Service
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to…
|
English | 27.7 KB |
Automate Your Workflow. Get a real-time feed of all Novartis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Novartis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Novartis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-30 | N/A | Executive member | Sell | None | 1,973,993.83 CHF |
| 2025-03-07 | N/A | Non-Executive member | Buy | None | 160,000.00 CHF |
| 2025-02-11 | N/A | Executive member | Sell | None | 312,203.18 CHF |
| 2025-02-07 | N/A | Executive member | Sell | None | 2,500,278.74 CHF |
| 2025-02-05 | N/A | Executive member | Sell | None | 1,365,687.19 CHF |
| 2025-02-04 | N/A | Executive member | Sell | None | 1,840,201.00 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 699,424.74 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 698,883.18 CHF |
| 2024-12-19 | N/A | Executive member | Sell | None | 1.00 CHF |
| 2024-11-29 | N/A | Executive member | Sell | None | 167,294.98 CHF |
